Skip to main content
. Author manuscript; available in PMC: 2023 Oct 26.
Published in final edited form as: J Med Chem. 2021 Aug 4;65(4):2880–2904. doi: 10.1021/acs.jmedchem.1c00598

Figure 2.

Figure 2.

Non-canonical binding mode of MLPCN HTS compound 6 (SID 24808289) and evolution to ML300 and related bi-phenyl analogs 7 and 8 originally developed for SARS-CoV-1 3CLpro. A) Schematic of binding mode of 6 orienting the binding site; B) Solvent accessible surface of SC1 3CLpro:6 complex, illustrating flexibility and reorganization of the binding pocket (PDB: 4MDS). C) Profile of 1 (ML300) and biaryl analogs 7 and 8.